

1 IN THE UNITED STATES DISTRICT COURT

2 FOR THE DISTRICT OF DELAWARE

3 - - - - - x

4 ALLERGAN, INC., :

5 Plaintiff, :

6 v. : C.A. NO. 17-663(JFB)(SEF)

7 TARO PHARMACEUTICAL :

8 INDUSTRIES LTD., and TARO :

9 PHARMACEUTICALS, INC., :

10 Defendants. :

11 - - - - - x

12 CONFIDENTIAL - UNDER THE PROTECTIVE ORDER

13  
14 Videotaped Deposition of KEVIN WARNER, PH.D.

15 Washington, D.C.

16 Wednesday, July 18, 2018

17 8:22 a.m.

18  
19 Job No.: 28438

20 Pages 1 through 349

21 Reported by: Cassandra E. Ellis, RPR

22

Page 2

1 Deposition of KEVIN WARNER, PH.D., held at the  
2 offices of Covington & Burling, LLP, 810 10th Street,  
3 Northwest, Washington, D.C. 20001, pursuant to  
4 agreement, before Cassandra E. Ellis, Certified Court  
5 Reporter - Washington, Certified Shorthand Reporter -  
6 Hawai'i, Registered Professional Reporter, Certified  
7 Livenote Reporter, Realtime Systems Administrator, and  
8 Notary Public of The District of Columbia.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22

Page 3

1 A P P E A R A N C E S  
2 ON BEHALF OF PLAINTIFF:  
3 CHANSON CHANG, ESQUIRE  
4 JIHONG LOU, ESQUIRE  
5 COVINGTON & BURLING, LLP  
6 850 10th Street, Northwest  
7 Washington, D.C. 20001  
8 (202) 662-5708  
9 Cchang@cov.com  
10  
11  
12 ON BEHALF OF DEFENDANT:  
13 STEPHEN P. BENSON, ESQUIRE  
14 KATTEN MUCHIN ROSENMAN, LLP  
15 Suite 1900  
16 525 W Monroe Street  
17 Chicago, Illinois 60661  
18 (312) 902-5200  
19 Stephen.benson@kattenlaw.com  
20  
21 ALSO PRESENT: Joseph E. Ellis, CLVS, AGCV  
22 Shenade Walker

Page 4

1	C O N T E N T S	
2	EXAMINATION OF KEVIN WARNER, PH.D.	PAGE
3	By Mr. Benson	10
4		
5		
6	E X H I B I T S	
7	(Attached to the Transcript)	
8	KEVIN WARNER, PH.D. Deposition Exhibit	PAGE
9	Exhibit 1 US Patent No. 9,517,219 B2 Bates	15
10	Stamped ALG_ACZ0000565-577	
11	Exhibit 2 Drug Product Information Bates	78
12	Stamped ALG_ACZ0264301-338	
13	Exhibit 3 Aczone NDA Storyline: Regulatory	81
14	Summary Bates Stamped ALG_ACZ0319637-655	
15	Exhibit 4 2/03/2012 E-Mail from Kevin Warner	113
16	Bates Stamped ALG_ACZ0226268-271	
17	Exhibit 5 Individual Project Agreement Bates	132
18	Stamped ALG_ACZ0236790-798	
19	Exhibit 6 Research Article Bates Stamped	149
20	ALG_ACZ0375158-165	
21	Exhibit 7 Sepineo P 600 Information Bates	153
22	Stamped ALG_ACZ0375156-157	

Page 5

1	E X H I B I T S C O N T I N U E D	
2	(Attached to the Transcript)	
3	KEVIN WARNER, PH.D. Deposition Exhibit	PAGE
4	Exhibit 8 1/25/2012 E-mail Bates Stamped	158
5	ALG_ACZ0316758-760	
6	Exhibit 9 Aczone Reformulation CQAs and Risk	172
7	Mitigation Update Bates Stamped	
8	ALG_ACZ0247034-042	
9	Exhibit 10 Dapsone/Adapalene Topical Gel	203
10	Formulation Summary Bates Stamped	
11	ALG_ACZ0174113-116	
12	Exhibit 11 12/02/2009 Dapsone Suspension	208
13	Product Update Bates Stamped	
14	ALG_ACZ0222016-021	
15	Exhibit 12 1/04/2010 Aczone Reformulation	222
16	Development Bates Stamped ALG_ACZ0246068-085	
17	Exhibit 13 2/03/2012 E-Mail from Ajay Parashar	229
18	Bates Stamped ALG_ACZ0313682-683	
19	Exhibit 14 Product Evaluation Bates Stamped	229
20	ALG_ACZ0313684-689	
21		
22		

EXHIBITS CONTINUED		Page 6
1	(Attached to the Transcript)	
3	KEVIN WARNER, PH.D. Deposition Exhibit	PAGE
4	Exhibit 15 Pharmaceutical Development Technical	237
5	Review Aczone Reformulation (Project #1679)	
6	Bates Stamped ALG_ACZ0249690-751	
7	Exhibit 16 3/29/2012 Memorandum PD-TMEMO-00561	288
8	Bates Stamped ALG_ACZ0314425-441	
9	Exhibit 17 Aczone Reformulation CMC Sub-Team	306
10	Team Meeting Minutes Bates Stamped	
11	ALG_ACZ0385496	
12	Exhibit 18 Development Report: FPD 137	324
13	Reformulation: Development of 7.5% Dapsone	
14	Gel Bates Stamped ALG_ACZ0248334-374	
15	Exhibit 19 11/07/2012 E-mail from Joan-En Lin	329
16	Bates Stamped ALG_ACZ0200675-676	
17	Exhibit 20 Dapsone Gel and Dapsone/ Adapalene	332
18	Fixed Dose Combination Gel Formulation	
19	Development Report; Effective Bates Stamped	
20	ALG_ACZ0249762-813	
21		
22		

EXHIBITS CONTINUED		Page 7
1	(Attached to the Transcript)	
3	KEVIN WARNER, PH.D. Deposition Exhibit	PAGE
4	Exhibit 21 Dapsone Gel and Dapsone/ Adapalene	332
5	Fixed Dose Combination Gel Formulation	
6	Development Report; Approved Bates Stamped	
7	ALG_ACZ0382881-932	
8	Exhibit 22 Declaration of Kevin S. Warner,	339
9	Ph.D. under 37 C.F.R. 4 1.132 Bates Stamped	
10	ALG_ACZ0000290-294	
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		

Page 8

[Redacted text block]

Page 9

[Redacted text block]

[Redacted text block for Page 10]

[Redacted text block for Page 11]

[Redacted text block for Page 12]

[Redacted text block for Page 13]

[Redacted text block]

[Redacted text block]

[Redacted text block]

[Redacted text block]

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.